Tuberculosis screening: Difference between revisions
Jump to navigation
Jump to search
Mohamed riad (talk | contribs) |
Mohamed riad (talk | contribs) |
||
| Line 8: | Line 8: | ||
===Mantoux Tuberculin Skin Test=== | ===Mantoux Tuberculin Skin Test=== | ||
* The [[Mantoux tuberculin skin test]] ([[Mantoux test|TST]]) is primarily used to evaluate a person whether they are infected with [[Mycobacterium tuberculosis]]. | *The [[Mantoux tuberculin skin test]] ([[Mantoux test|TST]]) is primarily used to evaluate a person whether they are infected with [[Mycobacterium tuberculosis]]. | ||
* The TST is done by intradermal injection 0.1 ml of [[tuberculin]] purified protein derivative ([[PPD]]) into the inner surface of the forearm. The injection is done using a [[Tuberculin test|tuberculin]] [[syringe]], with the needle bevel facing upward. In case of a correct injection, it produces a pale elevation of the skin ([[wheal]]) 6 to 10 mm in diameter. | *The TST is done by intradermal injection 0.1 ml of [[tuberculin]] purified protein derivative ([[PPD]]) into the inner surface of the forearm. The injection is done using a [[Tuberculin test|tuberculin]] [[syringe]], with the needle bevel facing upward. In case of a correct injection, it produces a pale elevation of the skin ([[wheal]]) 6 to 10 mm in diameter. | ||
* The reaction is read between 48 and 72 hours after administration. If the patient does not return within 72 hours, another [[Mantoux test|TST]] should be rescheduled. | *The reaction is read between 48 and 72 hours after administration. If the patient does not return within 72 hours, another [[Mantoux test|TST]] should be rescheduled. | ||
* The [[induration]] ([[Palpation|palpable]], raised, [[hardened]] area, or [[swelling]]) should be measured in millimeters not the [[erythema]] (redness), and the diameter of the indurated area is measured across the [[forearm]] (perpendicular to the long axis). | *The [[induration]] ([[Palpation|palpable]], raised, [[hardened]] area, or [[swelling]]) should be measured in millimeters not the [[erythema]] (redness), and the diameter of the indurated area is measured across the [[forearm]] (perpendicular to the long axis). | ||
* The only [[contraindication]] for TST is in persons who had any severe reaction (e.g., [[necrosis]], [[blister|blistering]], [[anaphylactic shock]], or [[ulcerations]]) to another previous [[Mantoux tuberculin skin test|TST]]. | *The only [[contraindication]] for TST is in persons who had any severe reaction (e.g., [[necrosis]], [[blister|blistering]], [[anaphylactic shock]], or [[ulcerations]]) to another previous [[Mantoux tuberculin skin test|TST]]. | ||
* TST is not [[Contraindication|contraindicated]] for any other individuals, including infants, children, pregnant women, [[Human Immunodeficiency Virus (HIV)|HIV]]-infected patients, or individuals who received [[BCG]] vaccination. | *TST is not [[Contraindication|contraindicated]] for any other individuals, including infants, children, pregnant women, [[Human Immunodeficiency Virus (HIV)|HIV]]-infected patients, or individuals who received [[BCG]] vaccination. | ||
* In some individuals with with previous [[M. tuberculosis]] infection, the reaction to [[tuberculin]] can wane over time, so if [[Mantoux tuberculin skin test|TST]] is done years after infection, it may yield [[False-negative test result|false-negative]] reaction. However, the [[Mantoux tuberculin skin test|TST]] may activate the immune system, leading to a positive, or boosted reaction to the following tests. Doing a second [[Mantoux test|TST]] after an initial negative TST reaction, that is known as two-step testing, is preferred especially for healthcare workers or nursing home residents (retested periodically). | *In some individuals with with previous [[M. tuberculosis]] infection, the reaction to [[tuberculin]] can wane over time, so if [[Mantoux tuberculin skin test|TST]] is done years after infection, it may yield [[False-negative test result|false-negative]] reaction. However, the [[Mantoux tuberculin skin test|TST]] may activate the immune system, leading to a positive, or boosted reaction to the following tests. Doing a second [[Mantoux test|TST]] after an initial negative TST reaction, that is known as two-step testing, is preferred especially for healthcare workers or nursing home residents (retested periodically). | ||
====Classification of Tuberculin Reaction==== | ====Classification of Tuberculin Reaction==== | ||
| Line 96: | Line 96: | ||
===Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis Clinics<small><small><small> Adapted from CDC<ref name="CDC HIV"> {{cite web| url=http://www.cdc.gov/tb/publications/factsheets/testing/HIVscreening.htm| title=CDC Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics}} </ref></small></small></small>=== | ===Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis Clinics<small><small><small> Adapted from CDC<ref name="CDC HIV"> {{cite web| url=http://www.cdc.gov/tb/publications/factsheets/testing/HIVscreening.htm| title=CDC Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics}} </ref></small></small></small>=== | ||
*CDC | *According to [[Centers for Disease Control and Prevention|CDC]], [[HIV]] screening is recommended for all [[Tuberculosis|TB]] patients after the patient notification that testing will be done unless the patient defers (i.e., [[opt-out]] [[Screening (medicine)|screening]]). This includes patients with TB disease and with [[latent TB]] infection. | ||
* | *[[HIV]] testing is also recommended for individuals who are suspected of having [[Tuberculosis|TB]] disease, patients with latent [[Tuberculosis|TB]] infection, and contacts of [[Tuberculosis|TB]] patients. | ||
*Prevention counseling and separate written consent for HIV testing | *Prevention counseling and separate written consent for HIV testing are no longer necessary. | ||
*These recommendations are aimed at eliminating missed opportunities for [[HIV]] screening and reducing significant barriers to HIV testing in health care settings by: | *These recommendations are aimed at eliminating missed opportunities for [[HIV]] screening and reducing significant barriers to HIV testing in health care settings by: | ||
:*Using opt-out [[HIV]] screening. | :*Using opt-out [[HIV]] screening. | ||
:*Annually screening persons at high risk for [[HIV]]. | :*Annually screening persons at high risk for [[HIV]]. | ||
:* | :*No need for separate written consent for [[HIV]] testing. | ||
:* | :*No need for prevention counseling for [[HIV]] screening. | ||
*Opt-out screening | *Opt-out screening refers to performing [[Human Immunodeficiency Virus (HIV)|HIV]] testing after informing the patient that the test will be done, and despite being declined by the patient, it is strongly recommended. Assent is inferred unless the patient defers [[Human Immunodeficiency Virus (HIV)|HIV]] testing. | ||
===Quantiferon Gold testing=== | ===Quantiferon Gold testing=== | ||
*The early | *The early identification of [[Mycobacterium tuberculosis]] infection is a complex issue regarding the control and prevention of TB.<ref name="urlWHO | Global tuberculosis report 2018, SYSTEM DO NOT MOVE OR EDIT">{{cite web |url=https://www.who.int/tb/publications/global_report/en/ |title=WHO | Global tuberculosis report 2018, SYSTEM DO NOT MOVE OR EDIT |format= |work= |accessdate=}}</ref> | ||
* | *Over several years, the tuberculin skin test ([[Mantoux test|TST]]) was the most commonly used test for the diagnosis of [[Tuberculosis|TB]] infection due to its low cost and convenience in most countries.<ref name="pmid27780211">{{cite journal |vauthors=Houben RM, Dodd PJ |title=The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling |journal=PLoS Med. |volume=13 |issue=10 |pages=e1002152 |date=October 2016 |pmid=27780211 |pmc=5079585 |doi=10.1371/journal.pmed.1002152 |url=}}</ref> | ||
*PPD testing has several disadvantages, including | *However, [[Mantoux test|PPD]] testing has several disadvantages, including low specificity in individuals who received the Bacille Calmette-Guerin (BCG) vaccination.<ref name="pmid17599309">{{cite journal |vauthors=Detjen AK, Keil T, Roll S, Hauer B, Mauch H, Wahn U, Magdorf K |title=Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis |journal=Clin. Infect. Dis. |volume=45 |issue=3 |pages=322–8 |date=August 2007 |pmid=17599309 |doi=10.1086/519266 |url=}}</ref> | ||
*In the last decade, interferon gamma release assays (IGRAs) have been | *In the last decade, [[interferon gamma release assays]] (IGRAs) have been used to detect Latent Tuberculosis.<ref name="pmid27039307">{{cite journal |vauthors=Lu P, Chen X, Zhu LM, Yang HT |title=Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis: A Systematic Review and Meta-analysis |journal=Lung |volume=194 |issue=3 |pages=447–58 |date=June 2016 |pmid=27039307 |doi=10.1007/s00408-016-9872-5 |url=}}</ref> | ||
*Interferon-gamma release assays (IGRAs) are immunodiagnostics | *[[Interferon-gamma release assays]] ([[Interferon-γ release assays|IGRAs]]) are immunodiagnostics techniques that measure [[interferon-gamma]] ([[IFN-γ]]) released by [[T cell|T-cells]] in response to [[Mycobacterium tuberculosis]]-specific antigen.<ref name="pmid17565023">{{cite journal |vauthors=Lalvani A |title=Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy |journal=Chest |volume=131 |issue=6 |pages=1898–906 |date=June 2007 |pmid=17565023 |doi=10.1378/chest.06-2471 |url=}}</ref> | ||
* | *There are two commercial in vitro [[Interferon-γ release assays|IGRAs]]; including the [[QuantiFERON-TB Gold]] In-Tube (QFT-GIT) test and [[T-SPOT.TB]] that have been used for for the early detection of [[Mycobacterium tuberculosis|M. tuberculosis]] infection.<ref name="pmid17565023">{{cite journal |vauthors=Lalvani A |title=Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy |journal=Chest |volume=131 |issue=6 |pages=1898–906 |date=June 2007 |pmid=17565023 |doi=10.1378/chest.06-2471 |url=}}</ref> | ||
* | *[[QuantiFERON-TB Gold]] includes [[proteins]] that are almost exclusively found in [[mycobacterium tuberculosis]].<ref name="pmid21099095">{{cite journal |vauthors=Dilektasli AG, Erdem E, Durukan E, Eyüboğlu FÖ |title=Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country? |journal=Jpn. J. Infect. Dis. |volume=63 |issue=6 |pages=433–6 |date=November 2010 |pmid=21099095 |doi= |url=}}</ref> | ||
*The QuantiFERON-TB Gold In-Tube test (QFT-GIT) assay | *[[The QuantiFERON-TB Gold]] In-Tube test (QFT-GIT) [[assay]] measures the [[Interferon|IFN]]-γ [[serum]] [[concentration]] following stimulation by specific [[Tuberculosis|TB]] [[Antigen|antigens]].<ref name="pmid21099095">{{cite journal |vauthors=Dilektasli AG, Erdem E, Durukan E, Eyüboğlu FÖ |title=Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country? |journal=Jpn. J. Infect. Dis. |volume=63 |issue=6 |pages=433–6 |date=November 2010 |pmid=21099095 |doi= |url=}}</ref> | ||
*The Quantiferon Gold test | *[[The Quantiferon Gold test]] is used on a large scale in developed countries.<ref name="pmid27039307">{{cite journal |vauthors=Lu P, Chen X, Zhu LM, Yang HT |title=Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis: A Systematic Review and Meta-analysis |journal=Lung |volume=194 |issue=3 |pages=447–58 |date=June 2016 |pmid=27039307 |doi=10.1007/s00408-016-9872-5 |url=}}</ref> | ||
* | *The ability of [[QFT-GIT]] will be to monitor the responses to [[anti-tuberculosis treatment]] is not fully-understood.<ref name="pmid17448540">{{cite journal |vauthors=Dheda K, Pooran A, Pai M, Miller RF, Lesley K, Booth HL, Scott GM, Akbar AN, Zumla A, Rook GA |title=Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results |journal=J. Infect. |volume=55 |issue=2 |pages=169–73 |date=August 2007 |pmid=17448540 |doi=10.1016/j.jinf.2007.02.005 |url=}}</ref> | ||
<br /> | <br /> | ||
Revision as of 05:06, 23 March 2021
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis screening On the Web |
|
American Roentgen Ray Society Images of Tuberculosis screening |
|
Risk calculators and risk factors for Tuberculosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Alejandro Lemor, M.D. [3]; Marjan Khan M.B.B.S.[4]
Overview
Tuberculosis screening is performed using a mantoux tuberculin skin test, also known as a tuberculin skin test or a PPD. This test is done by intradermal injection of a small amount of a purified protein derivative of the tuberculosis bacterium then observing the reaction in the following days.
Screening
Mantoux Tuberculin Skin Test
- The Mantoux tuberculin skin test (TST) is primarily used to evaluate a person whether they are infected with Mycobacterium tuberculosis.
- The TST is done by intradermal injection 0.1 ml of tuberculin purified protein derivative (PPD) into the inner surface of the forearm. The injection is done using a tuberculin syringe, with the needle bevel facing upward. In case of a correct injection, it produces a pale elevation of the skin (wheal) 6 to 10 mm in diameter.
- The reaction is read between 48 and 72 hours after administration. If the patient does not return within 72 hours, another TST should be rescheduled.
- The induration (palpable, raised, hardened area, or swelling) should be measured in millimeters not the erythema (redness), and the diameter of the indurated area is measured across the forearm (perpendicular to the long axis).
- The only contraindication for TST is in persons who had any severe reaction (e.g., necrosis, blistering, anaphylactic shock, or ulcerations) to another previous TST.
- TST is not contraindicated for any other individuals, including infants, children, pregnant women, HIV-infected patients, or individuals who received BCG vaccination.
- In some individuals with with previous M. tuberculosis infection, the reaction to tuberculin can wane over time, so if TST is done years after infection, it may yield false-negative reaction. However, the TST may activate the immune system, leading to a positive, or boosted reaction to the following tests. Doing a second TST after an initial negative TST reaction, that is known as two-step testing, is preferred especially for healthcare workers or nursing home residents (retested periodically).
Classification of Tuberculin Reaction
Interpretation of TST is based on on two elements:
- Measurement of the induration in millimeters.
- The individual’s risk of being infected with TB and also of progression to disease if infected.
   |
| Tuberculin Reaction | Considered a Positive Result in: |
|---|---|
| ≥ 5 mm |
|
| ≥ 10 mm |
|
| ≥ 15 mm |
|
| Table adapted from CDC[1] | |
| False-Positive Reactions | False-Negative Reactions |
|---|---|
In some cases, some individuals react to the TST positively although they are not infected with M. tuberculosis. The causes of these false-positive reactions involve, but are not limited to, the following:
|
On the other hand, Some individuals do not react to the TST although they are infected with M. tuberculosis. The causes for these false-negative reactions involve, but are not limited to, the following:
|
| Table adapted from CDC[1] | |
Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis Clinics Adapted from CDC[2]
- According to CDC, HIV screening is recommended for all TB patients after the patient notification that testing will be done unless the patient defers (i.e., opt-out screening). This includes patients with TB disease and with latent TB infection.
- HIV testing is also recommended for individuals who are suspected of having TB disease, patients with latent TB infection, and contacts of TB patients.
- Prevention counseling and separate written consent for HIV testing are no longer necessary.
- These recommendations are aimed at eliminating missed opportunities for HIV screening and reducing significant barriers to HIV testing in health care settings by:
- Opt-out screening refers to performing HIV testing after informing the patient that the test will be done, and despite being declined by the patient, it is strongly recommended. Assent is inferred unless the patient defers HIV testing.
Quantiferon Gold testing
- The early identification of Mycobacterium tuberculosis infection is a complex issue regarding the control and prevention of TB.[3]
- Over several years, the tuberculin skin test (TST) was the most commonly used test for the diagnosis of TB infection due to its low cost and convenience in most countries.[4]
- However, PPD testing has several disadvantages, including low specificity in individuals who received the Bacille Calmette-Guerin (BCG) vaccination.[5]
- In the last decade, interferon gamma release assays (IGRAs) have been used to detect Latent Tuberculosis.[6]
- Interferon-gamma release assays (IGRAs) are immunodiagnostics techniques that measure interferon-gamma (IFN-γ) released by T-cells in response to Mycobacterium tuberculosis-specific antigen.[7]
- There are two commercial in vitro IGRAs; including the QuantiFERON-TB Gold In-Tube (QFT-GIT) test and T-SPOT.TB that have been used for for the early detection of M. tuberculosis infection.[7]
- QuantiFERON-TB Gold includes proteins that are almost exclusively found in mycobacterium tuberculosis.[8]
- The QuantiFERON-TB Gold In-Tube test (QFT-GIT) assay measures the IFN-γ serum concentration following stimulation by specific TB antigens.[8]
- The Quantiferon Gold test is used on a large scale in developed countries.[6]
- The ability of QFT-GIT will be to monitor the responses to anti-tuberculosis treatment is not fully-understood.[9]
| Category | 2005 Recommendation | 2019 Recommendation |
|---|---|---|
| Baseline (preplacement) screening and testing | TB screening of all HCP, including a symptom evaluation and test (IGRA or TST) for those without documented prior TB disease or LTBI. | TB screening of all HCP, including a symptom evaluation and test (IGRA or TST) for those without documented prior TB disease or LTBI (unchanged); individual TB risk assessment (new). |
| Postexposure screening and testing | Symptom evaluation for all HCP when exposure is recognized. For HCP with a baseline negative TB test and no prior TB disease or LTBI, perform a test (IGRA or TST) when the exposure is identified. If that test is negative, do another test 8–10 weeks after the last exposure. | Symptom evaluation for all HCP when exposure is recognized. For HCP with a baseline negative TB test and no prior TB disease or LTBI, perform a test (IGRA or TST) when the exposure is identified. If that test is negative, do another test 8–10 weeks after the last exposure (unchanged). |
| Serial screening and testing for HCP without LTBI | According to health care facility and setting risk assessment. Not recommended for HCP working in low-risk health care settings. Recommended for HCP working in medium-risk health care settings and settings with potential ongoing transmission. | Not routinely recommended (new); can consider for selected HCP groups (unchanged); recommend annual TB education for all HCP (unchanged), including information about TB exposure risks for all HCP (new emphasis). |
| Evaluation and treatment of positive test results | Referral to determine whether LTBI treatment is indicated. | Treatment is encouraged for all HCP with untreated LTBI, unless medically contraindicated (new). |
| Abbreviations: IGRA = interferon-gamma release assay; LTBI = latent tuberculosis infection; TST = tuberculin skin test.
| ||
References
- ↑ 1.0 1.1 "CDC Tuberculin Skin Testing".
- ↑ "CDC Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics".
- ↑ "WHO | Global tuberculosis report 2018, SYSTEM DO NOT MOVE OR EDIT".
- ↑ Houben RM, Dodd PJ (October 2016). "The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling". PLoS Med. 13 (10): e1002152. doi:10.1371/journal.pmed.1002152. PMC 5079585. PMID 27780211.
- ↑ Detjen AK, Keil T, Roll S, Hauer B, Mauch H, Wahn U, Magdorf K (August 2007). "Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis". Clin. Infect. Dis. 45 (3): 322–8. doi:10.1086/519266. PMID 17599309.
- ↑ 6.0 6.1 Lu P, Chen X, Zhu LM, Yang HT (June 2016). "Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis: A Systematic Review and Meta-analysis". Lung. 194 (3): 447–58. doi:10.1007/s00408-016-9872-5. PMID 27039307.
- ↑ 7.0 7.1 Lalvani A (June 2007). "Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy". Chest. 131 (6): 1898–906. doi:10.1378/chest.06-2471. PMID 17565023.
- ↑ 8.0 8.1 Dilektasli AG, Erdem E, Durukan E, Eyüboğlu FÖ (November 2010). "Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country?". Jpn. J. Infect. Dis. 63 (6): 433–6. PMID 21099095.
- ↑ Dheda K, Pooran A, Pai M, Miller RF, Lesley K, Booth HL, Scott GM, Akbar AN, Zumla A, Rook GA (August 2007). "Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results". J. Infect. 55 (2): 169–73. doi:10.1016/j.jinf.2007.02.005. PMID 17448540.